TW202337444A - 解旋酶引子酶抑制劑的固體結晶形式及其製備方法 - Google Patents
解旋酶引子酶抑制劑的固體結晶形式及其製備方法 Download PDFInfo
- Publication number
- TW202337444A TW202337444A TW112101829A TW112101829A TW202337444A TW 202337444 A TW202337444 A TW 202337444A TW 112101829 A TW112101829 A TW 112101829A TW 112101829 A TW112101829 A TW 112101829A TW 202337444 A TW202337444 A TW 202337444A
- Authority
- TW
- Taiwan
- Prior art keywords
- degrees
- compound
- free base
- hcl salt
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22151820.2 | 2022-01-17 | ||
| EP22151820 | 2022-01-17 | ||
| EP22170332.5 | 2022-04-27 | ||
| EP22170332 | 2022-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202337444A true TW202337444A (zh) | 2023-10-01 |
Family
ID=84982261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112101829A TW202337444A (zh) | 2022-01-17 | 2023-01-16 | 解旋酶引子酶抑制劑的固體結晶形式及其製備方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250115565A1 (https=) |
| EP (1) | EP4466255A1 (https=) |
| JP (1) | JP2025502300A (https=) |
| KR (1) | KR20240134979A (https=) |
| AU (1) | AU2023206628A1 (https=) |
| CA (1) | CA3246779A1 (https=) |
| CL (1) | CL2024002124A1 (https=) |
| IL (1) | IL314188A (https=) |
| MX (1) | MX2024008821A (https=) |
| PY (1) | PY2302301A (https=) |
| TW (1) | TW202337444A (https=) |
| UY (1) | UY40111A (https=) |
| WO (1) | WO2023135303A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL319024A (en) * | 2022-08-29 | 2025-04-01 | Assembly Biosciences Inc | Pharmaceutical preparations for the herpes virus |
| IL325911A (en) | 2023-07-17 | 2026-03-01 | Innovative Molecules Gmbh | Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds |
| WO2026078039A1 (en) | 2024-10-09 | 2026-04-16 | Innovative Molecules Gmbh | Oral administration forms of antiviral helicase-primase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2000000109A (es) | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE10131128A1 (de) | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| GEP20207128B (en) | 2016-04-06 | 2020-07-10 | Molecules Gm Innovative | Aminothiazole derivatives useful as antiviral agents |
| MX2020003369A (es) | 2017-10-05 | 2020-07-29 | Innovative Molecules Gmbh | Enantiomeros de tiazoles sustituidos como compuestos antivirales. |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| KR20230131177A (ko) | 2020-10-29 | 2023-09-12 | 이노베이티브 몰리큘스 게엠베하 | 항바이러스 화합물로서 중수소화된 아미노티아졸 화합물 |
-
2023
- 2023-01-16 EP EP23700877.6A patent/EP4466255A1/en active Pending
- 2023-01-16 KR KR1020247027250A patent/KR20240134979A/ko active Pending
- 2023-01-16 JP JP2024542125A patent/JP2025502300A/ja active Pending
- 2023-01-16 TW TW112101829A patent/TW202337444A/zh unknown
- 2023-01-16 AU AU2023206628A patent/AU2023206628A1/en active Pending
- 2023-01-16 MX MX2024008821A patent/MX2024008821A/es unknown
- 2023-01-16 UY UY0001040111A patent/UY40111A/es unknown
- 2023-01-16 CA CA3246779A patent/CA3246779A1/en active Pending
- 2023-01-16 IL IL314188A patent/IL314188A/en unknown
- 2023-01-16 WO PCT/EP2023/050883 patent/WO2023135303A1/en not_active Ceased
- 2023-01-16 PY PY202302302301A patent/PY2302301A/es unknown
- 2023-01-16 US US18/729,411 patent/US20250115565A1/en active Pending
-
2024
- 2024-07-15 CL CL2024002124A patent/CL2024002124A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240134979A (ko) | 2024-09-10 |
| MX2024008821A (es) | 2024-07-29 |
| WO2023135303A1 (en) | 2023-07-20 |
| US20250115565A1 (en) | 2025-04-10 |
| PY2302301A (es) | 2023-10-31 |
| UY40111A (es) | 2023-08-15 |
| CA3246779A1 (en) | 2023-07-20 |
| IL314188A (en) | 2024-09-01 |
| AU2023206628A1 (en) | 2024-08-01 |
| EP4466255A1 (en) | 2024-11-27 |
| JP2025502300A (ja) | 2025-01-24 |
| CL2024002124A1 (es) | 2024-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12583821B2 (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
| TW202337444A (zh) | 解旋酶引子酶抑制劑的固體結晶形式及其製備方法 | |
| KR20210129128A (ko) | Fxr 효능제의 고체 형태 | |
| US8859567B2 (en) | Hydrate of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di-hydropyrido[3,4-D]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate | |
| JP2021535103A (ja) | グリコシダーゼ阻害剤として有用なピペラジン誘導体のコハク酸付加塩及びフマル酸付加塩 | |
| JP2015522037A (ja) | ベムラフェニブコリン塩の固体形態 | |
| TW202124373A (zh) | 1，3，5-三衍生物或其溶劑合物之結晶及其製造方法 | |
| JP2023552274A (ja) | 抗ウイルス化合物としての重水素化アミノチアゾール化合物 | |
| US20210130330A1 (en) | Solid forms of cerdulatinib | |
| TW202342466A (zh) | 二肽基肽酶抑制劑化合物的鹽及晶型 | |
| JP2024546844A (ja) | ピラゾロ［３，４－ｄ］ピリミジン化合物の固体形態 | |
| KR101557832B1 (ko) | (ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염 | |
| JP7252417B2 (ja) | Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール化合物の塩形、結晶形及びその製造方法 | |
| EP4063366A1 (en) | Crystal form of nucleoprotein inhibitor and use thereof | |
| CN121532378A (zh) | 抗病毒解旋酶-引发酶抑制剂化合物的微粉化结晶盐酸盐 | |
| CN118556045A (zh) | 解旋酶-引发酶抑制剂的固体结晶形式及其制备方法 | |
| HK40110051A (zh) | 解旋酶-引发酶抑制剂的固体结晶形式及其制备方法 | |
| EA052003B1 (ru) | Твердые кристаллические формы ингибиторов геликазы-примазы и способ их получения | |
| EP4610257A1 (en) | Crystal form of isoquinolinone compound and preparation method therefor | |
| US20130150453A1 (en) | Solid dapoxetine | |
| US12304905B2 (en) | Pharmaceutical salts of benzothiazol compounds, polymorphs and methods for preparation thereof | |
| RU2787767C2 (ru) | Кристалл производного бензоксазола | |
| WO2026017041A1 (zh) | 一种吡唑并喹唑啉类化合物及其盐型和晶型 | |
| CN108117570A (zh) | 一种替诺福韦艾拉酚胺半富马酸盐的结晶及其制备方法 | |
| TW202333694A (zh) | 稠環衍生物的晶型、其製備方法及其應用 |